{"id":108162,"date":"2025-05-18T00:30:15","date_gmt":"2025-05-18T00:30:15","guid":{"rendered":"https:\/\/www.europesays.com\/fr\/108162\/"},"modified":"2025-05-18T00:30:15","modified_gmt":"2025-05-18T00:30:15","slug":"et-si-les-dromadaires-permettaient-de-soigner-en-partie-la-maladie-dalzheimer-2","status":"publish","type":"post","link":"https:\/\/www.europesays.com\/fr\/108162\/","title":{"rendered":"Et si les dromadaires permettaient de soigner (en partie) la maladie d\u2019Alzheimer ?"},"content":{"rendered":"<p><strong>espoir &#8211; Des chercheurs du CNRS s\u2019inspirent du syst\u00e8me immunitaire des dromadaires pour d\u00e9velopper une piste th\u00e9rapeutique prometteuse contre la maladie d\u2019Alzheimer<\/strong><\/p>\n<p>Les dromadaires au secours des personnes atteintes d\u2019<a href=\"https:\/\/www.20minutes.fr\/dossier\/alzheimer?at_medium=RSS%20feed&amp;at_campaign=ynews&amp;utm_source=yahoo&amp;utm_medium=rss&amp;utm_campaign=news_feed&amp;utm_content=in_article_link\" rel=\"nofollow noopener\" target=\"_blank\" data-ylk=\"slk:Alzheimer;elm:context_link;itc:0;sec:content-canvas\" class=\"link \">Alzheimer<\/a>. Dans une vid\u00e9o publi\u00e9e il y a deux mois sur YouTube, une \u00e9quipe du <a href=\"https:\/\/www.20minutes.fr\/dossier\/cnrs?at_medium=RSS%20feed&amp;at_campaign=ynews&amp;utm_source=yahoo&amp;utm_medium=rss&amp;utm_campaign=news_feed&amp;utm_content=in_article_link\" rel=\"nofollow noopener\" target=\"_blank\" data-ylk=\"slk:CNRS;elm:context_link;itc:0;sec:content-canvas\" class=\"link \">CNRS<\/a> explique avoir explor\u00e9 des \u00ab\u00a0solutions issues des syst\u00e8mes immunitaires des cam\u00e9lid\u00e9s, comme les dromadaires ou les lamas\u00a0\u00bb pour envisager un traitement contre cette maladie neurod\u00e9g\u00e9n\u00e9rative, rapporte <a href=\"https:\/\/www.bfmtv.com\/sante\/une-future-therapie-contre-alzheimer-le-cnrs-avance-une-piste-prometteuse-grace-aux-dromadaires_AN-202505150274.html?at_medium=RSS%20feed&amp;at_campaign=ynews&amp;utm_source=yahoo&amp;utm_medium=rss&amp;utm_campaign=news_feed&amp;utm_content=in_article_link\" rel=\"nofollow noopener\" target=\"_blank\" data-ylk=\"slk:BFMTV;elm:context_link;itc:0;sec:content-canvas\" class=\"link \">BFMTV<\/a>. Les <a href=\"https:\/\/www.20minutes.fr\/dossier\/chercheurs?at_medium=RSS%20feed&amp;at_campaign=ynews&amp;utm_source=yahoo&amp;utm_medium=rss&amp;utm_campaign=news_feed&amp;utm_content=in_article_link\" rel=\"nofollow noopener\" target=\"_blank\" data-ylk=\"slk:chercheurs;elm:context_link;itc:0;sec:content-canvas\" class=\"link \">chercheurs<\/a> \u00e9tudient l\u2019utilisation de nanocorps anti-tau comme nouvelle piste th\u00e9rapeutique. <a href=\"https:\/\/www.insb.cnrs.fr\/fr\/cnrsinfo\/comprendre-alzheimer-des-petits-anticorps-prometteurs?at_medium=RSS%20feed&amp;at_campaign=ynews&amp;utm_source=yahoo&amp;utm_medium=rss&amp;utm_campaign=news_feed&amp;utm_content=in_article_link\" rel=\"nofollow noopener\" target=\"_blank\" data-ylk=\"slk:Un communiqu\u00e9;elm:context_link;itc:0;sec:content-canvas\" class=\"link \">Un communiqu\u00e9<\/a> publi\u00e9 ce lundi d\u00e9taille ces travaux parus dans la revue scientifique Nature Communications.<\/p>\n<p>\u00ab\u00a0Les <a href=\"https:\/\/www.20minutes.fr\/dossier\/maladie?at_medium=RSS%20feed&amp;at_campaign=ynews&amp;utm_source=yahoo&amp;utm_medium=rss&amp;utm_campaign=news_feed&amp;utm_content=in_article_link\" rel=\"nofollow noopener\" target=\"_blank\" data-ylk=\"slk:maladies;elm:context_link;itc:0;sec:content-canvas\" class=\"link \">maladies<\/a> neurod\u00e9g\u00e9n\u00e9ratives, comme la maladie d\u2019Alzheimer, se caract\u00e9risent par l\u2019accumulation anormale de certains variants prot\u00e9iques dans le cerveau. Ces prot\u00e9ines s\u2019agglutinent \u00e0 l\u2019int\u00e9rieur des neurones, perturbent leur fonctionnement et se propagent dans les cellules voisines\u00a0\u00bb, rappelle le CNRS. Dans le cas d\u2019Alzheimer, c\u2019est la prot\u00e9ine tau qui est en cause\u00a0: \u00ab\u00a0Chez les personnes atteintes, cette prot\u00e9ine change de forme et s\u2019agglutine dans les neurones.\u00a0\u00bb<\/p>\n<blockquote data-src=\"https:\/\/www.youtube.com\/embed\/sQbUBuVnED8?rel=0&amp;showinfo=1&amp;hl=fr-FR\" allowfullscreen=\"\" scrolling=\"no\"><\/blockquote>\n<p>La petite taille est un atout<\/p>\n<p>Les <a href=\"https:\/\/www.20minutes.fr\/dossier\/scientifiques?at_medium=RSS%20feed&amp;at_campaign=ynews&amp;utm_source=yahoo&amp;utm_medium=rss&amp;utm_campaign=news_feed&amp;utm_content=in_article_link\" rel=\"nofollow noopener\" target=\"_blank\" data-ylk=\"slk:scientifiques;elm:context_link;itc:0;sec:content-canvas\" class=\"link \">scientifiques<\/a> ont ainsi analys\u00e9 une s\u00e9rie de nanocorps anti-tau. Ces nanocorps sont de petits anticorps artificiels, issus d\u2019anticorps sp\u00e9cifiques des cam\u00e9lid\u00e9s. Parmi ceux \u00e9tudi\u00e9s, les d\u00e9nomm\u00e9s A31, Z70 et H3-2 se sont montr\u00e9s \u00ab\u00a0les inhibiteurs les plus puissants de l\u2019internalisation cellulaire de la prot\u00e9ine tau monom\u00e9rique dans les cultures de cellules neuronales de souris\u00a0\u00bb. Leur efficacit\u00e9 tiendrait \u00e0 leur tr\u00e8s petite taille.<\/p>\n<p>\u00ab\u00a0C\u2019es(&#8230;)<\/p>\n<p><a href=\"https:\/\/www.20minutes.fr\/sante\/4153938-20250517-si-dromadaires-permettaient-soigner-partie-maladie-alzheimer?at_medium=RSS%20feed&amp;at_campaign=ynews&amp;utm_source=yahoo&amp;utm_medium=rss&amp;utm_campaign=news_feed&amp;utm_content=read_more_link&quot;\" rel=\"nofollow noopener\" target=\"_blank\" data-ylk=\"slk:Lire la suite sur 20minutes;elm:context_link;itc:0;sec:content-canvas\" class=\"link \">Lire la suite sur 20minutes<\/a><\/p>\n<p>\u00c0 lire aussi :<br \/><a href=\"https:\/\/www.20minutes.fr\/sante\/4138849-20250214-patient-echappe-maladie-alzheimer-depuis-20-ans-scientifiques-veulent-comprendre-pourquoi?at_medium=RSS%20feed&amp;at_campaign=ynews&amp;utm_source=yahoo&amp;utm_medium=rss&amp;utm_campaign=news_feed&amp;utm_content=related_content_link\" rel=\"nofollow noopener\" target=\"_blank\" data-ylk=\"slk:Ce patient \u00ab\u00a0\u00e9chappe\u00a0\u00bb \u00e0 la maladie d\u2019Alzheimer depuis vingt ans, les scientifiques veulent comprendre pourquoi;elm:context_link;itc:0;sec:content-canvas\" class=\"link \">Ce patient \u00ab\u00a0\u00e9chappe\u00a0\u00bb \u00e0 la maladie d\u2019Alzheimer depuis vingt ans, les scientifiques veulent comprendre pourquoi<\/a><br \/><a href=\"https:\/\/www.20minutes.fr\/sante\/4134761-20250122-alzheimer-lien-entre-sommeil-maladie-neurodegenerative-etude-penche-question?at_medium=RSS%20feed&amp;at_campaign=ynews&amp;utm_source=yahoo&amp;utm_medium=rss&amp;utm_campaign=news_feed&amp;utm_content=related_content_link\" rel=\"nofollow noopener\" target=\"_blank\" data-ylk=\"slk:Alzheimer\u00a0: Y a-t-il un lien entre sommeil et maladie neurod\u00e9g\u00e9n\u00e9rative\u00a0? Une \u00e9tude se penche sur la question;elm:context_link;itc:0;sec:content-canvas\" class=\"link \">Alzheimer\u00a0: Y a-t-il un lien entre sommeil et maladie neurod\u00e9g\u00e9n\u00e9rative\u00a0? Une \u00e9tude se penche sur la question<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"espoir &#8211; Des chercheurs du CNRS s\u2019inspirent du syst\u00e8me immunitaire des dromadaires pour d\u00e9velopper une piste th\u00e9rapeutique prometteuse&hellip;\n","protected":false},"author":2,"featured_media":108163,"comment_status":"","ping_status":"","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[10],"tags":[5205,22599,1011,27,72,277,71,22598],"class_list":{"0":"post-108162","1":"post","2":"type-post","3":"status-publish","4":"format-standard","5":"has-post-thumbnail","7":"category-sante","8":"tag-cnrs","9":"tag-dromadaires","10":"tag-fr","11":"tag-france","12":"tag-health","13":"tag-maladie-dalzheimer","14":"tag-sante","15":"tag-systeme-immunitaire"},"share_on_mastodon":{"url":"https:\/\/pubeurope.com\/@fr\/114526016248413949","error":""},"_links":{"self":[{"href":"https:\/\/www.europesays.com\/fr\/wp-json\/wp\/v2\/posts\/108162","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.europesays.com\/fr\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.europesays.com\/fr\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/fr\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/fr\/wp-json\/wp\/v2\/comments?post=108162"}],"version-history":[{"count":0,"href":"https:\/\/www.europesays.com\/fr\/wp-json\/wp\/v2\/posts\/108162\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/fr\/wp-json\/wp\/v2\/media\/108163"}],"wp:attachment":[{"href":"https:\/\/www.europesays.com\/fr\/wp-json\/wp\/v2\/media?parent=108162"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.europesays.com\/fr\/wp-json\/wp\/v2\/categories?post=108162"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.europesays.com\/fr\/wp-json\/wp\/v2\/tags?post=108162"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}